INNOVA CAPTAB LIMITED
Plot No. 320, Industrial Area, Phase-1,
Panchkula, Pin-134113, Haryana, India.
Phone: +91-172-4194500

13th November, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex
Bandra (E), Mumbai – 400051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Press release

Pursuant to regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we are enclosing herewith the press release issued by the Company on the unaudited financial results for the quarter and half year ended 30th September, 2026.

The press release will also be available on the website of the Company at www.innovacaptab.com-press release.

This is for your information and record.

Thanking you,

Yours faithfully,
For and on behalf of Innova Captab Limited

NEEHARIKA SHUKLA
Digitally signed by NEEHARIKA SHUKLA
Date: 2026.11.13 18:22:02 +05'30'

Neeharika Shukla
Company Secretary and Compliance Officer

Encl.: A/a

INNOVA CAPTAB LIMITED

Press Release

Innova Captab Limited reported strong results for Q2 FY27, with Revenue from Operations at ₹ 496.3 crores and EBITDA at ₹ 72.4 crores

Mumbai, 13th November, 2026: Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its unaudited financial results for the quarter and half year ended September 30th, 2026.

Consolidated Financial Summary:

Particulars (₹ Crs.)	Q2FY27	Q2FY26	*YoY (%)*	H1FY27	H1FY26	*YoY (%)*
Revenue from operations	496.3	380.4	30.5%	967.2	731.9	32.1%
EBITDA	72.4	56.1	29.2%	147.5	112.6	31.0%
EBITDA Margin	*14.6%*	*14.7%*	*(10 bps)*	*15.3%*	*15.4%*	*(10 bps)*
PAT	42.4	29.7	43.0%	86.5	60.7	42.6%

Q2FY27 vs. Q2 FY26 Performance:

- Revenue from Operations registered strong growth of 30.5% to ₹ 496.3 crores vs. ₹ 380.4 crores
- EBITDA's growth stood at 29.2% to ₹ 72.4 crores vs. ₹ 56.1 crores. EBITDA margin for the quarter was 14.6%
- PAT for the quarter was ₹ 42.4 crores, registering growth of 43.0%. PAT margin was 8.5%

H1FY27 vs. H1FY26 Performance:

- Revenue from Operations registered strong growth of 32.1% to ₹ 967.2 crores vs. ₹ 731.9 crores
- EBITDA's growth stood at 31.0% to ₹ 147.5 crores vs. ₹ 112.6 crores. EBITDA margin for the half year was 15.3%
- PAT for the half year was ₹ 86.5 crores vs ₹ 60.7 crores, registering growth of 42.6%. PAT margin was 8.9%

Commenting on the company's performance, Mr. Vinay Lohariwala, Managing Director, Innova Captab Limited, said "Innova Captab Limited delivered a strong performance in Q2FY27, with revenue growing 30.5% YoY to ₹496.3 crore, EBITDA increasing 29.2% to ₹72.4 crore and PAT growing 43.0% to ₹42.4 crore.

The performance underscores the continued strength of our diversified business model and disciplined execution across our business operations.

The company continued to witness healthy business momentum across its CDMO and Branded Generics businesses, supported by a diversified product portfolio and deeper customer engagement. Our focus on operational excellence, manufacturing efficiency and quality continues to strengthen our competitive positioning and enables us to meet the evolving requirements of domestic and international markets. We are unequivocally focussed on continued Jammu ramp up alongside further strengthening of our manufacturing capabilities.
Going forward, the company remains committed to strengthen its CDMO positioning, expand its branded

generics presence and to ramp up manufacturing capacities. We remain confident of sustaining long term growth and value for stakeholders through our strategic roadmap focussing on timely and disciplined capital allocation decisions."

About Innova Captab Limited

Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company in India with a comprehensive business model and presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) business, the company provides an elaborate suit of pharmaceutical products to over 350 clients in India and key international markets. Apart from this, the company has strong direct presence across India and international markets with its Branded Generics Business. The company operates five state-of-the-art manufacturing facilities consisting of 9 independent blocks, accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA, PIC/s among others.
For more details, please visit www.innovacaptab.com

For more information, please contact:

Company Details	**Investor Relations Advisors**
Innova Captab Ltd. CIN: L24246MH2005PLC150371 **Mr. Lokesh Bhasin** **Email Id –** investors@innovacaptab.com www.innovacaptab.com	**Strategic Growth Advisors Pvt. Ltd.** CIN - U74140MH2010PTC204285 Ms. Shaily Patwa/ Mr. Shrikant Sangani Email - shaily.p@sgapl.net /shrikant.sangani@sgapl.net Mobile No – 9819494608 / 9619595686 www.sgapl.net

DISCLAIMER:
Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.